Evidence map›Paper›PMID 38238648›Full record

ArticleBMC cancer2024

Paclitaxel liposome (Lipusu) based chemotherapy combined with immunotherapy for advanced non-small cell lung cancer: a multicenter, retrospective real-world study.

Ran Li, Hongge Liang, Jun Li, Zhenyu Shao, Donghong Yang, Jing Bao, Keqiang Wang, Wen Xi, Zhancheng Gao, Renhua Guo and 1 more

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 2 pooled it
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Nanomedicine for Diagnosis and Treatment of Cardiac Fibrosis.International journal of nanomedicine · 2025
    Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Ran Li *Department of Respiratory and Critical Care Medicine, Lung Cancer Center, Peking University People's Hospital, No.11 Xizhimen South Street, Xicheng District, 100044, Beijing, China.
Hongge Liang *Department of Respiratory and Critical Care Medicine, Lung Cancer Center, Peking University People's Hospital, No.11 Xizhimen South Street, Xicheng District, 100044, Beijing, China.
Jun Li *Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, 210029, Nanjing, China.
Zhenyu ShaoDepartment of Radiation Oncology, Qilu Hospital of Shandong University, 250012, Jinan, China.
Donghong YangDepartment of Respiratory and Critical Care Medicine, Lung Cancer Center, Peking University People's Hospital, No.11 Xizhimen South Street, Xicheng District, 100044, Beijing, China.
Jing BaoDepartment of Respiratory and Critical Care Medicine, Lung Cancer Center, Peking University People's Hospital, No.11 Xizhimen South Street, Xicheng District, 100044, Beijing, China.
Keqiang WangDepartment of Respiratory and Critical Care Medicine, Lung Cancer Center, Peking University People's Hospital, No.11 Xizhimen South Street, Xicheng District, 100044, Beijing, China.
Wen XiDepartment of Respiratory and Critical Care Medicine, Lung Cancer Center, Peking University People's Hospital, No.11 Xizhimen South Street, Xicheng District, 100044, Beijing, China.
Zhancheng GaoDepartment of Respiratory and Critical Care Medicine, Lung Cancer Center, Peking University People's Hospital, No.11 Xizhimen South Street, Xicheng District, 100044, Beijing, China.
Renhua GuoDepartment of Oncology, The First Affiliated Hospital of Nanjing Medical University, 210029, Nanjing, China.
Xinlin MuDepartment of Respiratory and Critical Care Medicine, Lung Cancer Center, Peking University People's Hospital, No.11 Xizhimen South Street, Xicheng District, 100044, Beijing, China. xinlin169@163.com.
Peking University People's Hospital · CNPeking University · CNJiangsu Province Hospital · CNQilu Hospital of Shandong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPaclitaxel liposome (Lipusu) is known to be effective in non-small cell lung cancer (NSCLC) as first-line treatment. This study aimed to evaluate the effectiveness and safety of paclitaxel liposome based chemotherapy plus PD-1/PD-L1 inhibitor in patients with advanced NSCLC.

methodsIn this multicenter, retrospective, real-world study, patients with advanced NSCLC who were administered paclitaxel liposome based chemotherapy plus PD-1/PD-L1 inhibitor in three centers (Peking University People's Hospital as the lead center) in China between 2016 and 2022 were included. Progression-free survival (PFS), overall survival (OS), objective response rate, disease control rate, and adverse events (AEs) were evaluated.

resultsA total of 49 patients were included, with 33 (67.3%) receiving paclitaxel liposome based chemotherapy plus PD-1/PD-L1 inhibitor as first-line treatment. There were 34 patients (69.4%) diagnosed with squamous cell carcinoma and 15 (30.6%) with adenocarcinoma. The median follow-up was 20.5 (range: 3.1-41.1) months. The median PFS and OS of all patients were 9.7 months (95% confidence interval [CI], 7.0-12.4) and 30.5 months (95% CI, not evaluable-not evaluable), respectively. Patients with squamous cell carcinoma and adenocarcinoma had median PFS of 11 months (95%CI, 6.5-15.5) and 9.3 months (95%CI, 7.0-12.4), respectively. The median PFS was 9.9 months (95%CI, 7.1-12.7) in patients who received the combined regimen as first-line treatment. Treatment-related AEs of any grade were observed in 25 (51.0%) patients, and AEs of grade 3 or worse were observed in nine patients (18.4%). The most common treatment-related AEs were myelosuppression (14.3%) and fever (10.2%).

conclusionsPaclitaxel liposome based chemotherapy plus PD-1/PD-L1 inhibitor prolonged the PFS in advanced NSCLC with acceptable safety, which was worthy of clinical application.

Indexed as

AdenocarcinomaCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellLung NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansImmune Checkpoint InhibitorsImmunotherapyLiposomesPaclitaxelProgrammed Cell Death 1 ReceptorRetrospective StudiesImmune Checkpoint InhibitorsLiposomesPaclitaxelProgrammed Cell Death 1 ReceptorImmune checkpoint inhibitorImmunotherapyNon-small cell lung cancerPaclitaxel liposome

Identifiers

PMID38238648
PMCPMC10797919
OpenAlexW4390973826

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.